3h agoSeeking AlphaBEARISH 34Earnings
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset
Cue Biopharma (CUE) stock plunges 31% despite positive CUE-221 phase 2 urticaria data vs Xolair. Read more here.
Why Is CUE BIOPHARMA INC (CUE) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 10 wire stories
CUE BIOPHARMA INC (CUE) is drawing unusual attention today. Our newswire has captured 10 stories on CUE across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for CUE publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
CUE by the numbers
Coverage: 10 stories / 8 sourcesAI sentiment: 64/100 (bullish)
The headlines behind the move
3h agoSeeking AlphaBULLISH 73Product/PR
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria September 21, 2026 8:00 AM EDTCompany...
3h agoMarketChameleonBULLISH 73Product/PR
Cue Biopharma spotlights durable CSU response as CUE-221 holds benefit 12 weeks after last dose September 21, 2026
Cue Biopharma reported positive topline Phase 2 results for CUE-221 in chronic spontaneous urticaria, meeting the primary endpoint of complete hives resolution (HSS7=0) at Week 12 across all dose levels versus placebo. The top 4 mg/kg dose also achieved a statistically significant complete response (UAS7=0) and showed durability, with 60% hive-free at Week 28—12 weeks after the last dose—alongside a favorable safety profile.
6h agoSEC 8-KNEUTRAL 50General
Cue Biopharma, Inc. (CUE) files 8-K
Filed: 2026-09-21 AccNo: 0001193125-26-396094 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
7h agoMarketChameleonBULLISH 73Product/PR
Cue Biopharma’s CUE-221 posts statistically significant Phase 2 CSU results, with Week 28 separation versus omalizumab September 21, 2026
Cue Biopharma reported positive topline Phase 2 results for CUE-221 in chronic spontaneous urticaria, with dose-responsive Week 12 hive clearance and statistical significance versus placebo across all dose levels for the primary endpoint. The highest dose also showed durability, with 60% achieving HSS7=0 at Week 28 (12 weeks off treatment) and a post hoc statistically significant separation versus omalizumab (delta 36%).
7h agoInvestorsHubBULLISH 73Earnings
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
Cue Biopharma shares surge 41.6% premarket after its CUE-221 Phase 2 trial meets primary and key secondary endpoints in chronic spontaneous urticaria.
10h agoInvesting.com MarketsNEUTRAL 50General
Why is Cue Biopharma stock surging today?
Why is Cue Biopharma stock surging today?
1d agoThe FlyBULLISH 67Product/PR
Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint
1d agoGlobeNewswireBULLISH 73Earnings
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile Clinically different efficacy profile observed relative to XOLAIR ® ...
1d agoBusiness InsiderBULLISH 73Product/PR
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile Clinically different efficacy profile observed relative to XOLAIR ® ...
Frequently asked questions
Why is CUE stock moving today?
CUE BIOPHARMA INC (CUE) is drawing unusual attention today. Our newswire has captured 10 stories on CUE across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100). The most recent driver: "Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset" (Seeking Alpha).
Is CUE a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CUE coverage reads 64/100 over 10 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is GRAL up today (+34.87%)
- Why is ARM up today (+16.40%)
- Why is EMAT down today (-15.92%)
- Why is SECZ up today (+14.92%)
- Why is YSS up today (+14.39%)
- Why is FSLY up today (+14.18%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on CUE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.